Achilles Therapeutics (ACHL) shares were up 1.1% Tuesday morning after the company said it sold certain technology assets to AstraZeneca (AZN) for $12 million.
The company said it transferred a commercial license of proprietary data and samples from the TRACERx non-small cell lung cancer study to AstraZeneca.
Achilles said the sale concludes a strategic review it had first announced in September. The company said it now plans to further reduce its employee headcount and decrease the size of its board.
Price: 0.99, Change: +0.01, Percent Change: +1.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments